Clinical Trial Update: Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether omega-3 fatty acid supplementation lowers coronary artery disease risk in people with schizophrenia or schizoaffective disorder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Coronary Artery Disease
• Major Depressive Disorder
• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Omega-3 Fatty Acid Supplement (omega-3 fatty acids)

Snippet

Sponsor: University of Pittsburgh | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: COMPLETED | Results posted: 2017-04-10